Brought to you by 
Kolltan Pharmaceuticals raises $8.5mm in Series B round
29 Jan 2010
Executive Summary
Kolltan Pharmaceuticals (oncology therapeutics start-up) has raised $8.5mm through the sale of Series B convertible preferred shares to an affiliate of private equity firm Celtic Therapeutics Holdings LLLP (lead) and Tichenor Ventures LLC. The company could add another $1.5mm to this amount should the Celtic affiliate exercise a product development option. Kolltan, founded in 2007, raised $40mm through a Series A round completed in August of last year.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kolltan Pharmaceuticals raises $8.5mm in Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice